Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DBH | P09172 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6110916 | 0.81 | IDO1 (0.50) | IDO1PNMTTAAR1CARM1ALDH1A1 | |
| SCHEMBL5227562 | 0.77 | IDO1 (0.49) | IDO1PNMTTAAR1CARM1KMT2A | |
| SCHEMBL16341750 | 0.76 | CNR1 (0.43) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL697645 | 0.74 | IDO1 (0.53) | IDO1PNMTTAAR1CARM1KMT2A | |
| SCHEMBL694529 | 0.74 | IDO1 (0.45) | IDO1PNMTTAAR1CARM1CYP1A2 | |
| SCHEMBL1151976 | 0.70 | MAOB (0.44) | IDO1CYP1A2MAPTCYP2C19NR4A2 | |
| SCHEMBL2721265 | 0.69 | IDO1 (0.48) | IDO1PNMTMAPTFABP4FABP5 | |
| SCHEMBL547586 | 0.68 | IDO1 (0.69) | IDO1PNMTTAAR1CARM1KMT2A | |
| SCHEMBL995345 | 0.68 | IDO1 (0.69) | IDO1PNMTTAAR1CARM1KMT2A | |
| SCHEMBL12877184 | 0.67 | IDO1 (0.67) | IDO1PNMTTAAR1CARM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262364-B1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | VTV THERAPEUTICS LLC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-9120813-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | VTV THERAPEUTICS LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | VTV THERAPEUTICS LLC | 2015-03-26 | — | — | US | disclosed |
| US-8933222-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140187769-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | TRANSTECH PHARMA, LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-8703766-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130317015-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8524708-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-7906507-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2262364-A2 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TransTech Pharma, Inc (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7790714-B2 | treating non-insulin dependent diabetes comprising administering a glucagon-like peptide receptor modulators such as (S)-2-({(S)-6-benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid | TRANSTECH PHARMA, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7727983-B2 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANSTECH PHARMA, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANS TECH. PHARMA. INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009111700-A2 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187769-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | GLP1R, INSR, GPR119 | IDO1 698/4885PNMT 2581/4885TAAR1 728/4885 |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | IDO1 628/4885PNMT 2297/4885TAAR1 946/4885 |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | GLP1R, GIPR, GCGR | IDO1 1243/4885PNMT 4249/4885TAAR1 303/4885 |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | IDO1 628/4885PNMT 2297/4885TAAR1 946/4885 |
| US-20130317015-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | IDO1 674/4885PNMT 2159/4885TAAR1 792/4885 |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | IDO1 628/4885PNMT 2297/4885TAAR1 946/4885 |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | GLP1R, GPR119, OTC | IDO1 674/4885PNMT 2159/4885TAAR1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.